Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00OCI
|
||||
| Former ID |
DNCL001640
|
||||
| Drug Name |
CNTO-136
|
||||
| Synonyms |
Sirukumab
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Cutaneous lupus erythematosus [ICD9: 710; ICD10:M32] | Phase 3 | [1] | ||
| Company |
Centocor Ortho Biotech
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-6 receptor | Target Info | [2] | ||
| KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
| HIF-1 signaling pathway | |||||
| PI3K-Akt signaling pathway | |||||
| Jak-STAT signaling pathway | |||||
| Hematopoietic cell lineage | |||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Reactome | MAPK3 (ERK1) activation | ||||
| MAPK1 (ERK2) activation | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Senescence and Autophagy in Cancer | |||||
| IL-6 signaling pathway | |||||
| Differentiation Pathway | |||||
| Interleukin-6 signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01856309) Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.